Company Scinai Immunotherapeutics Ltd.

Stocks

SCNI

US09073Q4029

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-06 EDT			5-day change	1st Jan Change
1.220 ^USD	-3.17%		-17.01%	-82.87%

08-26	Scinai Immunotherapeutics Ltd., H1 2026 Earnings Call, Aug 26, 2026
08-24	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Business description: Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Companyâ€™s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Number of employees: 45

Sales by Activity: Scinai Immunotherapeutics Ltd.

Fiscal Period: December	2021 (ILS)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Pharmaceuticals	-	-	-	658K	1.31M

See all business segments

Geographical breakdown of sales: Scinai Immunotherapeutics Ltd.

Fiscal Period: December	2021 (ILS)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Israel	-	-	-	658K	1.31M

See all geographic segments

Executive Committee: Scinai Immunotherapeutics Ltd.

Manager	Title	Age	Since
Amir Reichman CEO	Chief Executive Officer	51	2021-03-01
Uri Ben-Or DFI	Director of Finance/CFO	55	2006-12-31
Dalit Fischer CTO	Chief Tech/Sci/R&D Officer	-	2021-12-31
Elad Mark COO	Chief Operating Officer	44	2019-08-31
Tamar Ben-Yedidia CTO	Chief Tech/Sci/R&D Officer	63	2003-12-31

See SCINAI IMMUNOTHERAPEUTICS LTD. governance

Composition of the Board of Directors: Scinai Immunotherapeutics Ltd.

Director	Title	Age	Since
Mark Germain CHM	Chairman	77	2019-09-29
Samuel Moed BRD	Director/Board Member	64	2020-03-23
Adi Raviv BRD	Director/Board Member	71	2020-03-23
Amir Reichman BRD	Director/Board Member	51	2021-03-01
Jay Green BRD	Director/Board Member	54	2021-12-26
Yael Margolin BRD	Director/Board Member	73	2018-12-31

Composition of the Board of Directors

Shareholders: Scinai Immunotherapeutics Ltd.

Name	Stocks	%	Valuation
Citadel Securities GP LLC 1.204 %	6,226	1.204 %	15 565 $
Armistice Capital LLC 0.6952 %	3,594	0.6952 %	8 985 $
Virtu Financial LLC 0.377 %	1,949	0.377 %	4 873 $
XTX Topco Ltd. 0.3242 %	1,676	0.3242 %	4 190 $
RhumbLine Advisers LP 0.2613 %	1,351	0.2613 %	3 378 $

Name	Stocks	%	Valuation
Daniel Stone 9.9 %	1,985,328,000	9.9 %	12 M $
Rk Stone Miami LLC 7.121 %	1,428,024,000	7.121 %	9 M $
Lck Jnk 1 LLC 6.33 %	1,269,464,000	6.33 %	8 M $
Amir Reichman 0.3368 %	67,540,000	0.3368 %	422 125 $
Elad Mark 0.0972 %	19,488,000	0.0972 %	121 800 $

List of SCINAI IMMUNOTHERAPEUTICS LTD. shareholders

Company details: Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

Jerusalem BioPark

74036, Jerusalem

+972 8 930 2529

http://www.scinai.com

address Scinai Immunotherapeutics Ltd.(SCNI)

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCINAI IMMUNOTHERAPEUTICS LTD.	-3.17%	-17.01%	-90.83%	-98.26%	718K
WUXI APPTEC CO., LTD.	+4.16%	+3.42%	+49.37%	+94.17%	74.31B
ARGENX SE	+2.76%	-1.16%	+23.05%	+83.03%	56.95B
LONZA GROUP AG	+0.24%	-1.37%	+4.08%	+37.22%	48.3B
REVOLUTION MEDICINES, INC.	-3.76%	-0.93%	+327.90%	+691.25%	44.51B
IQVIA HOLDINGS INC.	-2.30%	-4.06%	+25.82%	+31.42%	43.8B
BEONE MEDICINES AG	+0.31%	-1.15%	+5.50%	+112.56%	41.12B
CELLTRION, INC.	-0.11%	+2.30%	+9.19%	+58.68%	31.07B
WUXI BIOLOGICS (CAYMAN) INC.	+4.51%	+8.43%	+37.27%	+34.97%	28.97B
BIONTECH SE	-1.96%	-3.38%	-9.25%	-12.85%	24.53B
Average	+0.36%	-1.61%	+38.21%	+103.22%	39.36B
Weighted average by Cap.	+1.10%	-0.50%	+56.58%	+134.21%